

# Cancer Prevention and Research Institute of Texas Funding (CPRIT)



## Legislative Ask

ACS CAN supports full funding of \$600 million for the Cancer Prevention Research Institute Texas in the biennium budget, ensuring that Texas remains a leader in cancer prevention and research.

## CPRIT Makes Texas a Leader in the Fight Against Cancer

- As of the end of Fiscal Year 2022, CPRIT had awarded more than \$2 billion in academic research grants to almost three dozen research institutions and organizations across Texas. <sup>i</sup>
- As a result of CPRIT's investment in active cancer research, Texas institutions have raised over \$2.5 billion in additional funding. <sup>ii</sup>
- The CPRIT Prevention program continues to invest in effective community-based interventions that utilize new technologies and innovative approaches to reach more Texans and work to decrease the burden of cancer. <sup>ii</sup>
- CPRIT has funded over 8 million prevention services to Texans in all 254 counties, reaching Texans who otherwise would do without. <sup>ii</sup>
- 251 new clinical studies with 40,165 patients <sup>i</sup>
- 14,250 cancer precursors and 3,492 cancers detected <sup>i</sup>
- Nationally recognized teams and centers in immunotherapy and childhood cancers
- CPRIT investments have resulted in an additional \$839 billion in direct non-state follow-on funding. <sup>i</sup>
- The CPRIT investment impact has been a tremendous boost to the Texas economy with the annual gross impact of CPRIT on Texas business activity almost \$31.9 billion in annual spending, \$15.6 billion in output each year, and 151,587 jobs in 2020. <sup>i</sup>

## ACS CAN's Support of CPRIT

- The American Cancer Society (ACS) and ACS CAN have supported the creation and continued funding of CPRIT.
- ACS and ACS CAN are not directly involved in the CPRIT grant process.
- ACS and ACS CAN do not receive any CPRIT funds.

---

<sup>i</sup> CPRIT 2023 Annual Report,

<sup>ii</sup> CPRIT Real Momentum □ Measurable Results, November 18, 2020